Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional, and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabet Res Clin Pract. 2022;183: 109119.

Article  Google Scholar 

Mendivil CO, Amaya-Montoya M, Hernández-Vargas JA, Ramírez-García N, Romero-Díaz C, Pérez-Londoño A, et al. Achievement of treatment goals among adults with diabetes in Colombia, 2015–2019: results from a national registry. Diabet Res Clin Pract. 2022;186: 109823.

Article  Google Scholar 

Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–7.

Article  PubMed  Google Scholar 

Pharmacologic Approaches to Glycemic Treatment. Standards of care in diabetes-2024. Diabetes Care. 2024;47(Suppl 1):S158–78.

Google Scholar 

Aroda VR, Ahmann A, Cariou B, Chow F, Davies MJ, Jódar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials. Diabetes Metab. 2019;45(5):409–18.

Article  CAS  PubMed  Google Scholar 

Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

Article  CAS  PubMed  Google Scholar 

Rodríguez JE, Campbell KM. Racial and ethnic disparities in prevalence and care of patients with type 2 diabetes. Clin Diabet. 2017;35(1):66–70.

Article  Google Scholar 

Kelley AT, Mizokami-Stout K, O’Brien MJ, Bowen ME, Sussman J. Hispanic representation in diabetes cardiovascular outcomes trials. BMJ Open Diabetes Res Care. 2019;7(1): e000656.

Article  PubMed  PubMed Central  Google Scholar 

Rajamand Ekberg N, Bodholdt U, Catarig AM, Catrina SB, Grau K, Holmberg CN, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study. Prim Care Diabetes. 2021;15(5):871–8.

Article  CAS  PubMed  Google Scholar 

Rudofsky G, Catarig AM, Favre L, Grau K, Häfliger S, Thomann R, Schultes B. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabet Res Clin Pract. 2021;178: 108931.

Article  CAS  Google Scholar 

Holmes P, Bell HE, Bozkurt K, Catarig AM, Clark A, Machell A, Sathyapalan T. Real-world use of once-weekly semaglutide in type 2 diabetes: results from the SURE UK multicentre, prospective observational study. Diabetes Ther. 2021;12(11):2891–905.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Napoli R, Berra C, Catarig AM, Di Loreto C, Donatiello E, Berentzen TL, et al. Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study. Diabetes Obes Metab. 2023;25(6):1658–67.

Article  CAS  PubMed  Google Scholar 

Menzen M, Berentzen TL, Catarig AM, Pieperhoff S, Simon J, Jacob S. Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany. Exp Clin Endocrinol Diabet Off J German Soc Endocrinol German Diabet Assoc. 2023;131(4):205–15.

Wolffenbuttel BHR, Brugts MP, Catarig AM, Clark A, Kok M, Lieverse AG, van Soest J. Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE Netherlands observational study. Adv Ther. 2023;40(3):920–33.

Article  CAS  PubMed  Google Scholar 

Bellido V, Abreu Padín C, Catarig AM, Clark A, Barreto Pittol S, Delgado E. Once-Weekly Semaglutide Use in Patients with Type 2 Diabetes: Results from the SURE Spain Multicentre, Prospective, Observational Study. J Clin Med. 2022;11(17).

Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023;25(7):1855–64.

Article  CAS  PubMed  Google Scholar 

Yale JF, Catarig AM, Grau K, Harris S, Klimek-Abercrombie A, Rabasa-Lhoret R, et al. Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicentre, prospective, observational study. Diabetes Obes Metab. 2021;23(10):2269–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, Randomized Clinical Trial. Diabetes care. 2018;41(2):258–66.

Article  CAS  PubMed  Google Scholar 

Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5(5):341–54.

Article  PubMed  Google Scholar 

Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(5):355–66.

Article  CAS  PubMed  Google Scholar 

Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, Tadayon S, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100–9.

Lingvay I, Catarig AM, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(11):834–44.

Article  CAS  PubMed  Google Scholar 

Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2(4):289–97.

Article  CAS  PubMed  Google Scholar 

Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103(6):2291–301.

Article  PubMed  PubMed Central  Google Scholar 

Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115(9):1447–63.

Article  PubMed  Google Scholar 

Wong MCS, Wang HHX, Kwan MWM, Chan WM, Fan CKM, Liang M, et al. The adoption of the reference framework for diabetes care among primary care physicians in primary care settings: a cross-sectional study. Medicine. 2016;95(31): e4108.

Article  PubMed  PubMed Central  Google Scholar